BioRestorative Completes Phase 2 Trial for BRTX-100
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 13 2025
0mins
BioRestorative Therapies Inc. saw its stock rise by 21.39% as it crossed above the 20-day SMA, following the completion of its Phase 2 clinical trial for BRTX-100 in chronic lumbar disc disease.
The company has successfully completed treatment administration in its Phase 2 trial involving 99 patients, with topline safety and efficacy data expected in Q2 2027. The FDA's Type B meeting raised no clinical safety concerns and confirmed key elements of the late-stage development pathway, demonstrating regulatory support for the project. This progress indicates strong potential for BRTX-100 as an innovative treatment for chronic low back pain.
The completion of the Phase 2 trial not only highlights the efficacy of BRTX-100 but also allows BioRestorative to focus on its BioCosmeceutical platform, showcasing the company's long-term growth potential in regenerative medicine.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BRTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BRTX
Wall Street analysts forecast BRTX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.208
Low
8.00
Averages
8.00
High
8.00
Current: 0.208
Low
8.00
Averages
8.00
High
8.00
About BRTX
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioRestorative Completes Phase 2 Trial for BRTX-100 in Chronic Lumbar Disc Disease
- Clinical Trial Progress: BioRestorative has completed treatment administration in its Phase 2 clinical trial for BRTX-100, involving 99 patients, marking a significant milestone in addressing chronic lumbar disc disease, with topline safety and efficacy data expected in Q2 2027.
- FDA Meeting Outcomes: The company’s Type B meeting with the FDA raised no clinical safety concerns and aligned on key elements of the late-stage development pathway, laying a solid foundation for the Phase 3 trial preparations and demonstrating regulatory support for the project.
- Innovative Treatment Method: BRTX-100 is an autologous mesenchymal stem cell therapy delivered via a single intradiscal injection of 40 x 10^6 cells, aimed at alleviating chronic low back pain, with no dose-limiting toxicities or serious adverse events reported during the trial, indicating strong safety profiles.
- Future Development Strategy: With the completion of Phase 2 dosing, BioRestorative plans to redirect resources towards additional value-creation priorities, including the commercialization of its BioCosmeceutical platform, showcasing the company’s long-term growth potential in regenerative medicine.
See More
BioRestorative Completes Phase 2 Trial for BRTX-100 in Chronic Lumbar Disc Disease
- Clinical Trial Progress: BioRestorative has completed the Phase 2 clinical trial of BRTX-100 in 99 patients, marking a significant milestone in the treatment of chronic lumbar disc disease, with topline safety and efficacy data expected in Q2 2027.
- Successful FDA Alignment: The company’s Type B meeting with the FDA raised no clinical safety concerns and confirmed key elements of the Phase 2 trial, laying a solid foundation for subsequent Phase 3 readiness activities and demonstrating regulatory confidence in its development pathway.
- Preliminary Efficacy Data: BioRestorative reported favorable safety and preliminary efficacy data from the Phase 2 trial, with significant improvements in pain and functional measures across multiple follow-up periods, indicating the potential of BRTX-100 in treating chronic low back pain.
- Strategic Resource Reallocation: With the completion of Phase 2 dosing, the company plans to reduce expenses and redirect operational focus towards the commercialization of its BioCosmeceutical platform, aiming to create additional value through a diversified product line.
See More
BioRestorative Presents New MSC-Derived Exosome Data
- Clinical Data Presentation: BioRestorative showcased new preclinical data at the 2026 International Society for Cell & Gene Therapy meeting, highlighting functional and proteomic differences in extracellular vesicles from various mesenchymal stem cell sources, which may enhance the company's competitive edge in regenerative medicine and aesthetics.
- Targeted Therapeutic Applications: The study indicates that exosomes derived from umbilical cord, brown adipose tissue, and bone marrow exhibit unique protein signatures that support cellular growth and tissue regeneration, potentially laying the groundwork for developing products aimed at specific clinical and commercial applications.
- Integrated Biological Platform: The CEO of BioRestorative emphasized that exosomes and other extracellular vesicle-based biologics are central to their comprehensive regenerative platform, aiming to align biological functions with clinical outcomes to enhance structured and targeted product development.
- Cosmeceutical Product Development: The company plans to leverage these functional insights to design products targeting skin rejuvenation, anti-aging, and wound repair, further expanding its BioCosmeceutical platform to meet market demand for effective skincare solutions.
See More
BioRestorative Reports Positive Phase 2 Trial Results for BRTX-100
- Clinical Trial Update: BioRestorative presented updated data on BRTX-100 at ISCT 2026, revealing that 52% of evaluable patients achieved at least 50% improvement in both VAS and ODI measures at 52 weeks, indicating the therapy's potential for chronic lumbar disc disease treatment.
- Increased Patient Evaluation: The number of patients evaluated at 52 weeks rose from 12 to 25, reflecting enhanced participation in the clinical trial, while no adverse events related to dose-limiting toxicities were observed, further validating the safety profile of BRTX-100.
- Sustained Efficacy: Across multiple validated measures including VAS, ODI, RMDQ, and FRI, 56% of patients reported at least 50% improvement at 52 weeks, with average improvement rates reaching 73.8% at 104 weeks, demonstrating the therapy's sustained and stable efficacy.
- FDA Fast Track Designation: BRTX-100 has received Fast Track designation from the FDA, aimed at expediting development and review, with BioRestorative planning to submit a Phase 3 IND application later in 2026 to further advance the clinical progress of this therapy.
See More
BioRestorative to Present New Data at ISCT 2026 Annual Meeting
- Clinical Trial Progress: BioRestorative will present safety and blinded efficacy data from its Phase 2 clinical trial for chronic lumbar disc disease at the 2026 ISCT Annual Meeting, which is expected to bolster investor confidence in its therapeutic solutions.
- Technology Innovation Showcase: The company will introduce preclinical data on its MSC exosome platform, indicating potential applications in therapeutic and cosmetic fields, which may open new avenues for future product development.
- FDA Approval Milestone: BRTX-100 has received Investigational New Drug (IND) clearance from the FDA for treating chronic cervical discogenic pain, marking a significant milestone in the company's clinical development and potentially accelerating market entry.
- Broad Market Potential: BioRestorative's biopharmaceutical platform combines cell therapies with bio-cosmetic products, which is expected to attract significant market demand for anti-aging and metabolic disease solutions, further enhancing the company's competitive position.
See More
BioRestorative Partners with Dermatologist to Enhance BioCosmeceutical Platform
- Strategic Partnership: BioRestorative Therapies, Inc. (BRTX) has formed a strategic partnership with renowned dermatologist Dr. David J. Goldberg to accelerate clinical validation and market adoption of its regenerative BioCosmeceutical platform, which is expected to significantly enhance brand influence and market penetration.
- Clinical Study Leadership: Dr. Goldberg will lead a prospective, controlled human clinical study evaluating BioRestorative's biologics, enriched with exosomes, growth factors, cytokines, and peptides, aimed at generating comparative outcome data on skin improvements relative to current aesthetic benchmarks, thereby driving both scientific and commercial advancement.
- Market Expansion Potential: With Dr. Goldberg's involvement, BioRestorative anticipates expanding access to influential physician networks, enhancing brand positioning, and supporting evidence-based adoption across clinics and consumer markets, further driving its penetration in professional and consumer sectors.
- Infrastructure Development: This partnership represents the third pillar of BioRestorative's broader strategy for its BioCosmeceutical business, combining cleanroom manufacturing capabilities and commercial execution with 203 Creates, aimed at establishing the necessary infrastructure to compete in the rapidly growing regenerative aesthetics market.
See More
BioRestorative Completes Phase 2 Trial for BRTX-100 in Chronic Lumbar Disc Disease
- Clinical Trial Progress: BioRestorative has completed treatment administration in its Phase 2 clinical trial for BRTX-100, involving 99 patients, marking a significant milestone in addressing chronic lumbar disc disease, with topline safety and efficacy data expected in Q2 2027.
- FDA Meeting Outcomes: The company’s Type B meeting with the FDA raised no clinical safety concerns and aligned on key elements of the late-stage development pathway, laying a solid foundation for the Phase 3 trial preparations and demonstrating regulatory support for the project.
- Innovative Treatment Method: BRTX-100 is an autologous mesenchymal stem cell therapy delivered via a single intradiscal injection of 40 x 10^6 cells, aimed at alleviating chronic low back pain, with no dose-limiting toxicities or serious adverse events reported during the trial, indicating strong safety profiles.
- Future Development Strategy: With the completion of Phase 2 dosing, BioRestorative plans to redirect resources towards additional value-creation priorities, including the commercialization of its BioCosmeceutical platform, showcasing the company’s long-term growth potential in regenerative medicine.
See More
BioRestorative Completes Phase 2 Trial for BRTX-100 in Chronic Lumbar Disc Disease
- Clinical Trial Progress: BioRestorative has completed the Phase 2 clinical trial of BRTX-100 in 99 patients, marking a significant milestone in the treatment of chronic lumbar disc disease, with topline safety and efficacy data expected in Q2 2027.
- Successful FDA Alignment: The company’s Type B meeting with the FDA raised no clinical safety concerns and confirmed key elements of the Phase 2 trial, laying a solid foundation for subsequent Phase 3 readiness activities and demonstrating regulatory confidence in its development pathway.
- Preliminary Efficacy Data: BioRestorative reported favorable safety and preliminary efficacy data from the Phase 2 trial, with significant improvements in pain and functional measures across multiple follow-up periods, indicating the potential of BRTX-100 in treating chronic low back pain.
- Strategic Resource Reallocation: With the completion of Phase 2 dosing, the company plans to reduce expenses and redirect operational focus towards the commercialization of its BioCosmeceutical platform, aiming to create additional value through a diversified product line.
See More
BioRestorative Presents New MSC-Derived Exosome Data
- Clinical Data Presentation: BioRestorative showcased new preclinical data at the 2026 International Society for Cell & Gene Therapy meeting, highlighting functional and proteomic differences in extracellular vesicles from various mesenchymal stem cell sources, which may enhance the company's competitive edge in regenerative medicine and aesthetics.
- Targeted Therapeutic Applications: The study indicates that exosomes derived from umbilical cord, brown adipose tissue, and bone marrow exhibit unique protein signatures that support cellular growth and tissue regeneration, potentially laying the groundwork for developing products aimed at specific clinical and commercial applications.
- Integrated Biological Platform: The CEO of BioRestorative emphasized that exosomes and other extracellular vesicle-based biologics are central to their comprehensive regenerative platform, aiming to align biological functions with clinical outcomes to enhance structured and targeted product development.
- Cosmeceutical Product Development: The company plans to leverage these functional insights to design products targeting skin rejuvenation, anti-aging, and wound repair, further expanding its BioCosmeceutical platform to meet market demand for effective skincare solutions.
See More
BioRestorative Reports Positive Phase 2 Trial Results for BRTX-100
- Clinical Trial Update: BioRestorative presented updated data on BRTX-100 at ISCT 2026, revealing that 52% of evaluable patients achieved at least 50% improvement in both VAS and ODI measures at 52 weeks, indicating the therapy's potential for chronic lumbar disc disease treatment.
- Increased Patient Evaluation: The number of patients evaluated at 52 weeks rose from 12 to 25, reflecting enhanced participation in the clinical trial, while no adverse events related to dose-limiting toxicities were observed, further validating the safety profile of BRTX-100.
- Sustained Efficacy: Across multiple validated measures including VAS, ODI, RMDQ, and FRI, 56% of patients reported at least 50% improvement at 52 weeks, with average improvement rates reaching 73.8% at 104 weeks, demonstrating the therapy's sustained and stable efficacy.
- FDA Fast Track Designation: BRTX-100 has received Fast Track designation from the FDA, aimed at expediting development and review, with BioRestorative planning to submit a Phase 3 IND application later in 2026 to further advance the clinical progress of this therapy.
See More
BioRestorative to Present New Data at ISCT 2026 Annual Meeting
- Clinical Trial Progress: BioRestorative will present safety and blinded efficacy data from its Phase 2 clinical trial for chronic lumbar disc disease at the 2026 ISCT Annual Meeting, which is expected to bolster investor confidence in its therapeutic solutions.
- Technology Innovation Showcase: The company will introduce preclinical data on its MSC exosome platform, indicating potential applications in therapeutic and cosmetic fields, which may open new avenues for future product development.
- FDA Approval Milestone: BRTX-100 has received Investigational New Drug (IND) clearance from the FDA for treating chronic cervical discogenic pain, marking a significant milestone in the company's clinical development and potentially accelerating market entry.
- Broad Market Potential: BioRestorative's biopharmaceutical platform combines cell therapies with bio-cosmetic products, which is expected to attract significant market demand for anti-aging and metabolic disease solutions, further enhancing the company's competitive position.
See More
BioRestorative Partners with Dermatologist to Enhance BioCosmeceutical Platform
- Strategic Partnership: BioRestorative Therapies, Inc. (BRTX) has formed a strategic partnership with renowned dermatologist Dr. David J. Goldberg to accelerate clinical validation and market adoption of its regenerative BioCosmeceutical platform, which is expected to significantly enhance brand influence and market penetration.
- Clinical Study Leadership: Dr. Goldberg will lead a prospective, controlled human clinical study evaluating BioRestorative's biologics, enriched with exosomes, growth factors, cytokines, and peptides, aimed at generating comparative outcome data on skin improvements relative to current aesthetic benchmarks, thereby driving both scientific and commercial advancement.
- Market Expansion Potential: With Dr. Goldberg's involvement, BioRestorative anticipates expanding access to influential physician networks, enhancing brand positioning, and supporting evidence-based adoption across clinics and consumer markets, further driving its penetration in professional and consumer sectors.
- Infrastructure Development: This partnership represents the third pillar of BioRestorative's broader strategy for its BioCosmeceutical business, combining cleanroom manufacturing capabilities and commercial execution with 203 Creates, aimed at establishing the necessary infrastructure to compete in the rapidly growing regenerative aesthetics market.
See More
